QV Bioelectronics develops implantable electric field therapy devices designed to treat glioblastoma following surgical tumor resection. The company’s lead system, GRACE, is engineered to deliver localized electric fields directly to the tumor site after surgery. Its approach focuses on targeting residual cancer cells during the critical post-operative period. QV Bioelectronics positions its technology within regulated oncological and neurosurgical care pathways.

The technology delivers controlled electric fields to the resection cavity, where microscopic tumor cells often remain. These fields are designed to disrupt cellular processes involved in tumor cell division and migration, slowing recurrence. The implant is placed during surgery and operates locally, avoiding the need for external hardware during treatment. This approach emphasizes precision targeting while minimizing impact on surrounding healthy tissue.

QV Bioelectronics targets patients with glioblastoma, an aggressive brain cancer with high recurrence rates despite standard treatment. The GRACE system is intended to complement surgery, chemotherapy, and radiotherapy within established clinical protocols. Its positioning reflects broader interest in localized, device-based cancer therapies that address disease progression at the site of origin.